Literature DB >> 15491141

Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.

Sebastien Spagnou1, Andrew D Miller, Michael Keller.   

Abstract

RNA interference (RNAi) has become a popular tool for downregulating specific gene expression in many species, including mammalian cells [Novina, C. D., and Sharp, P. A. (2004) The RNAi revolution, Nature 430, 161-164]. Synthetic double-stranded RNA sequences (siRNA) of 21-23 nucleotides have been shown in particular to have the potential to silence specifically gene function in cultured mammalian cells. As a result, there has been a significant surge of interest in the application of siRNA in functional genomics programs as a means of deciphering specific gene function. However, for siRNA functional genomics studies to be valuable and effective, specific silencing of any given target gene is essential, devoid of nonspecific knockdown and toxic side effects. For this reason, we became interested in investigating cationic liposome/lipid-mediated siRNA delivery (siFection) as a meaningful and potentially potent way to facilitate effective functional genomics studies. Accordingly, a number of cationic liposome/lipid-based systems were selected, and their formulation with siRNA was studied, with particular emphasis on formulation parameters most beneficial for siRNA use in functional genomics studies. Cationic liposome/lipid-based systems were selected from a number of commercially available products, including lipofectAMINE2000 and a range of CDAN/DOPE systems formulated from different molar ratios of the cationic cholesterol-based polyamine lipid N(1)-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine (CDAN) and the neutral helper lipid dioleoyl-L-alpha-phosphatidylethanolamine (DOPE). Parameters that were been investigated included the lipid:nucleic acid ratio of mixing, the extent of cationic liposome/lipid-nucleic acid complex (lipoplex) formation plus medium used, the lipoplex particle size, the mode of delivery, and dose-response effects. Results suggest that concentrations during siRNA lipoplex (LsiR) formation are crucial for maximum knockdown, but the efficacy of gene silencing is not influenced by the size of LsiR particles. Most significantly, results show that most commercially available cationic liposome/lipid-based systems investigated here mediate a significant nonspecific downregulation of the total cellular protein content at optimal doses for maximal specific gene silencing and knockdown. Furthermore, one pivotal aspect of using siRNA for functional genomics studies is the need for at least minimal cellular toxicity. Results demonstrate that CDAN and DOPE with and without siRNA confer low toxicity to mammalian cells, whereas lipofectAMINE2000 is clearly toxic both as a reagent and after formulation into LsiR particles. Interestingly, LsiR particles formulated from CDAN and DOPE (45:55, m/m; siFECTamine) seem to exhibit a slower cellular uptake than LsiR particles formulated from lipofectAMINE2000. Intracellularly, LsiR particles formulated from CDAN and DOPE systems also appear to behave differently, amassing in distinct but diffuse small nonlysosomal compartments for at least 5 h after siFection. By contrast, LsiR particles formulated from lipofectAMINE2000 accumulate in fewer larger intracellular vesicles.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15491141     DOI: 10.1021/bi048950a

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  88 in total

Review 1.  Silence of the transcripts: RNA interference in medicine.

Authors:  Sailen Barik
Journal:  J Mol Med (Berl)       Date:  2005-07-19       Impact factor: 4.599

Review 2.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

Review 3.  Matrices and scaffolds for DNA delivery in tissue engineering.

Authors:  Laura De Laporte; Lonnie D Shea
Journal:  Adv Drug Deliv Rev       Date:  2007-04-14       Impact factor: 15.470

4.  Multilayer mediated forward and patterned siRNA transfection using linear-PEI at extended N/P ratios.

Authors:  Sumit Mehrotra; Ilsoon Lee; Christina Chan
Journal:  Acta Biomater       Date:  2009-01-19       Impact factor: 8.947

Review 5.  Liposomal siRNA nanocarriers for cancer therapy.

Authors:  Bulent Ozpolat; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2013-12-30       Impact factor: 15.470

6.  Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery.

Authors:  Oleh Taratula; Olga B Garbuzenko; Paul Kirkpatrick; Ipsit Pandya; Ronak Savla; Vitaly P Pozharov; Huixin He; Tamara Minko
Journal:  J Control Release       Date:  2009-06-28       Impact factor: 9.776

7.  Global gene expression profiling in cultured cells is strongly influenced by treatment with siRNA-cationic liposome complexes.

Authors:  Tatsuaki Tagami; Kiyomi Hirose; Jose Mario Barichello; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

8.  Fluid flow induces mechanosensitive ATP release, calcium signalling and Cl- transport in biliary epithelial cells through a PKCzeta-dependent pathway.

Authors:  Kangmee Woo; Amal K Dutta; Vishal Patel; Charles Kresge; Andrew P Feranchak
Journal:  J Physiol       Date:  2008-04-03       Impact factor: 5.182

Review 9.  Lipidic systems for in vivo siRNA delivery.

Authors:  Sherry Y Wu; Nigel A J McMillan
Journal:  AAPS J       Date:  2009-09-09       Impact factor: 4.009

10.  Recent developments in peptide-based nucleic acid delivery.

Authors:  Sandra Veldhoen; Sandra D Laufer; Tobias Restle
Journal:  Int J Mol Sci       Date:  2008-07-16       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.